Nicholas A. Lopardo Sells 2,000 Shares of PerkinElmer, Inc. (PKI) Stock

PerkinElmer, Inc. (NYSE:PKI) Director Nicholas A. Lopardo sold 2,000 shares of the company’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $87.08, for a total value of $174,160.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Nicholas A. Lopardo also recently made the following trade(s):

  • On Monday, November 5th, Nicholas A. Lopardo sold 2,000 shares of PerkinElmer stock. The stock was sold at an average price of $82.12, for a total value of $164,240.00.

NYSE:PKI opened at $86.66 on Thursday. The stock has a market cap of $9.64 billion, a PE ratio of 29.88, a price-to-earnings-growth ratio of 1.93 and a beta of 1.12. PerkinElmer, Inc. has a 1 year low of $69.21 and a 1 year high of $98.33. The company has a quick ratio of 1.18, a current ratio of 1.70 and a debt-to-equity ratio of 0.73.

PerkinElmer (NYSE:PKI) last announced its earnings results on Wednesday, October 31st. The medical research company reported $0.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.02). The firm had revenue of $674.30 million during the quarter, compared to analyst estimates of $676.72 million. PerkinElmer had a net margin of 4.71% and a return on equity of 15.04%. The firm’s revenue for the quarter was up 21.7% compared to the same quarter last year. During the same period last year, the company earned $0.73 earnings per share. As a group, research analysts forecast that PerkinElmer, Inc. will post 3.6 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, February 8th. Investors of record on Friday, January 18th will be given a $0.07 dividend. The ex-dividend date is Thursday, January 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.32%. PerkinElmer’s dividend payout ratio (DPR) is presently 9.66%.

PKI has been the topic of several recent research reports. Cleveland Research upgraded PerkinElmer from a “neutral” rating to a “buy” rating in a report on Thursday, August 30th. Morgan Stanley upped their price target on PerkinElmer from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Wednesday, October 10th. Janney Montgomery Scott downgraded PerkinElmer from a “buy” rating to a “neutral” rating in a report on Friday, November 2nd. Deutsche Bank upped their price target on PerkinElmer from $88.00 to $93.00 and gave the stock a “hold” rating in a report on Monday, September 10th. Finally, Barclays upgraded PerkinElmer from an “underweight” rating to an “equal weight” rating and upped their price target for the stock from $79.00 to $90.00 in a report on Wednesday, September 5th. Eight research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. PerkinElmer currently has a consensus rating of “Hold” and an average target price of $87.84.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Kohmann Bosshard Financial Services LLC purchased a new position in shares of PerkinElmer during the 3rd quarter worth approximately $107,000. Twin Tree Management LP raised its stake in shares of PerkinElmer by 135.8% during the 2nd quarter. Twin Tree Management LP now owns 2,549 shares of the medical research company’s stock worth $187,000 after buying an additional 9,674 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of PerkinElmer by 69.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 1,972 shares of the medical research company’s stock worth $191,000 after buying an additional 806 shares in the last quarter. Ibex Investors LLC purchased a new position in shares of PerkinElmer during the 3rd quarter worth approximately $206,000. Finally, Conning Inc. purchased a new position in shares of PerkinElmer during the 3rd quarter worth approximately $212,000. 94.82% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Nicholas A. Lopardo Sells 2,000 Shares of PerkinElmer, Inc. (PKI) Stock” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.wkrb13.com/2018/12/06/nicholas-a-lopardo-sells-2000-shares-of-perkinelmer-inc-pki-stock.html.

About PerkinElmer

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers analytical technologies, solutions, and services for the environmental market that enable its customers to understand the characterization and health of various aspects, including air, water, and soil.

Further Reading: What is a capital gain?

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply